Labcorp’s New Alzheimer’s Blood Test Might Change The Case For Investing In Labcorp Holdings (LH)

Simply Wall St

Sun, February 15, 2026 at 2:12 AM GMT+9 3 min read

In this article:

LH

+1.63%

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying symptomatic patients aged 55+ who are unlikely to have amyloid pathology.

This test broadens access to Alzheimer’s assessment through a simple blood draw, potentially easing specialist bottlenecks and shifting more initial evaluation into primary care.

Next, we’ll examine how expanding Alzheimer’s blood diagnostics into primary care may influence Labcorp’s existing investment narrative and growth assumptions.

We’ve uncovered the 13 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.

Labcorp Holdings Investment Narrative Recap

To own Labcorp, you need to believe it can convert its broad test menu, hospital partnerships and technology investments into steady volume and margin improvement despite reimbursement and regulatory pressures. The Elecsys pTau-181 Alzheimer’s blood test launch looks incrementally positive for Labcorp’s neurology testing franchise, but it does not materially change the near term focus on reimbursement risk, including potential PAMA impacts, or competitive pricing pressure in core diagnostics.

The Elecsys pTau-181 rollout connects directly to Labcorp’s push into higher value neurology and specialty testing, alongside recent minimal residual disease launches in oncology. Together, these offerings support the existing thesis that new assays in complex disease areas can help offset pricing pressure in more routine testing and partially counterbalance macro and regulatory headwinds, even if the Alzheimer’s primary care opportunity will likely build over time.

Yet, against this innovation backdrop, investors still need to watch the unresolved PAMA reimbursement overhang and what it could mean for…

Read the full narrative on Labcorp Holdings (it’s free!)

Labcorp Holdings’ narrative projects $15.6 billion revenue and $1.3 billion earnings by 2028.

Uncover how Labcorp Holdings’ forecasts yield a $300.06 fair value, a 6% upside to its current price.

Exploring Other Perspectives

LH 1-Year Stock Price Chart

Members of the Simply Wall St Community see Labcorp’s fair value anywhere between US$200 and about US$594, reflecting very different expectations. When you set those views against the importance of reimbursement and pricing risk in diagnostics, it underlines why you might want to compare several perspectives before forming your own.

Explore 4 other fair value estimates on Labcorp Holdings - why the stock might be worth over 2x more than the current price!

Story Continues  

Build Your Own Labcorp Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

Interested In Other Possibilities?

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

Find 53 companies with promising cash flow potential yet trading below their fair value.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 28 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include LH.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info